Euronext Paris Growth Companies With High Insider Ownership For August 2024

In This Article:

As hopes for a soft landing grow in the U.S., European markets, including France, have shown strong gains, with the CAC 40 Index advancing by 2.48%. In this favorable market environment, growth companies with high insider ownership can be particularly attractive due to their potential for robust performance and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In France

Name

Insider Ownership

Earnings Growth

Groupe OKwind Société anonyme (ENXTPA:ALOKW)

24.8%

36%

VusionGroup (ENXTPA:VU)

13.4%

25.7%

Adocia (ENXTPA:ADOC)

11.9%

63%

Icape Holding (ENXTPA:ALICA)

30.2%

35.1%

Arcure (ENXTPA:ALCUR)

21.4%

27.5%

La Fran?aise de l'Energie (ENXTPA:FDE)

19.9%

31.9%

S.M.A.I.O (ENXTPA:ALSMA)

17.4%

35.2%

Munic (ENXTPA:ALMUN)

29.2%

149.2%

MedinCell (ENXTPA:MEDCL)

15.8%

93.9%

OSE Immunotherapeutics (ENXTPA:OSE)

25.6%

5.9%

Click here to see the full list of 23 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Lectra

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture markets across Northern and Southern Europe, the Americas, and the Asia Pacific with a market cap of €1.03 billion.

Operations: The company's revenue segments are as follows: €172.65 million from the Americas and €118.54 million from the Asia Pacific, with a segment adjustment of €209.13 million.

Insider Ownership: 19.6%

Revenue Growth Forecast: 10.4% p.a.

Lectra, a French growth company with high insider ownership, reported half-year sales of €262.29 million, up from €239.55 million last year, though net income decreased to €12.51 million from €14.47 million. Despite this dip in profitability, analysts expect Lectra's revenue to grow at 10.4% annually and earnings at 29.3%, both outpacing the French market averages of 5.8% and 12.2%, respectively, suggesting strong future potential despite current challenges.

ENXTPA:LSS Earnings and Revenue Growth as at Aug 2024
ENXTPA:LSS Earnings and Revenue Growth as at Aug 2024

MedinCell

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A., with a market cap of €527.07 million, is a pharmaceutical company in France that develops long-acting injectables across various therapeutic areas.

Operations: MedinCell generates its revenue primarily from the pharmaceuticals segment, amounting to €11.95 million.

Insider Ownership: 15.8%

Revenue Growth Forecast: 45.9% p.a.